Nationwide Children's Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nationwide Children's Hospital sits in the top decile of US sponsors by registered trial count (#158 of 15,742 sponsors by registered trial count).
Nationwide Children's Hospital: 188 sponsored US clinical trials, 29 recruiting.
Nationwide Children's Hospital sponsors 188 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 122 completed. 13 of these trials are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is High Grade Glioma, with 8 trials.
Top-decile sponsor footprint
Nationwide Children's Hospital ranks in the top decile of sponsors by registered trial count (#158 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
122 of 143 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
188 total, page 1 of 4
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
NCT06333899
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
NCT06838676
Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy
NCT06503367
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
NCT04254419
Pediatric Cochlear Implant Remote Programming and Assessment
NCT07035873
Preparing for Life and Academics for Young Childhood Cancer Survivors
NCT06769334
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
NCT05843253
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
NCT05096481
Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness
NCT06264700
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
NCT06114836
Improving Status Epilepticus Treatment Times
NCT06194747
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
NCT06082947
DOSC and Association With Neighborhood Opportunity: Phase II
NCT05939570
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05286788
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05233397
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT05278208
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
NCT05634369
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
NCT04211675
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
NCT05135975
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
NCT05503134
Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
NCT04722029
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
NCT04655404
Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
NCT04467671
Early Predictors of Necrotizing Enterocolitis in Neonates
NCT03210831
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
NCT03622359
Genetics of Congenital Heart Disease
NCT01192048
Metabolomic Profiling of Racial Disparity
NCT06266429
Regional Anesthesia EMG Study
NCT06287151
VR-PAT for Pain and Anxiety Management During Pediatric Dermatologic Laser Procedures
NCT05645224
Evaluating an Intervention to Prevent Overdoses in Rural and Urban Counties
NCT05463341
Natural History Study of Patients With VCP-related Disease
NCT04823143
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
NCT03782610
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
NCT03769844
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
NCT03605550
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
NCT03431090
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
NCT02972580
MIBG Therapy for Patients With MIBG Avid Tumors
NCT02378428
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
NCT03520751
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain
NCT06303687
Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
NCT07026942
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
NCT05779930
Spanish BMT4me Usability & Acceptability
NCT06361173
Preoperative Survey to Evaluate Patient Allergy
NCT05670756
A Pilot Study of Collaborative Assessment and Management of Suicidality With Suicidal Children ("CAMS-4Kids")
NCT04119648
Baclofen for Children With Rumination Syndrome
NCT05975684
Psychologically Informed Education Intervention for Adolescents With Atraumatic Lower-Extremity Injuries
NCT05701618
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 29 |
| Phase 3 | 8 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the Nationwide Children's Hospital pipeline
29 recruiting of 188 indexed (15% open); 122 completed (65%).
Phase mix: 13 late (III/IV) vs 50 early (I/II) (early-phase heavy).
Top condition: High Grade Glioma (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nationwide Children's Hospital: open-pipeline peers nationwide
Peers matched on 188 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Nationwide Children's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 188 trials (± recruiting share)
- Vanderbilt-Ingram Cancer Center · 189 trials · 15% recruiting
- Arizona State University · 187 trials · 15% recruiting
- Johns Hopkins Bloomberg School of Public Health · 187 trials · 14% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
Related
What to do with this Nationwide Children's Hospital page
188 registered trials is a research-attention snapshot, not an endorsement of Nationwide Children's Hospital or any single study.
- 29 of Nationwide Children's Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- High Grade Glioma is the condition Nationwide Children's Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See High Grade Glioma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nationwide Children's Hospital pipeline card: 188 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.